Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo


Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

 10-347 The Liver Tumor Tissue Bio Repository Main Campus  Liver
 16-903 Intermediate Size Expanded Access Protocol (EAP) Main Campus  Myelofibrosis
 14-351 A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmapheresis with infusion of human albumin combined with intravenous immunoglobulin in patients with mild-moderate Alzheimer’s disease. Main Campus  Alzheimer’s disease
07-267  Collection of Blood and Tissue from Patients with Upper Aerodigestive Malignancies for Research Purposes (The UAM Tissue Resource) Main Campus  Esophageal, Head & Neck, Lung, Mesothelioma, Thyroid
2559  Genetic and molecular analysis of tumors of the Nervous system and their coverings Main Campus  Brain
3952  Collection of Blood and Bone Marrow from Allogeneic Hematopoietic Cell Transplant Recipients and their Related Donors Main Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
4639  Tissue and Body Fluid Analysis from Renal Cell Cancer Patients Main Campus  Renal
5024  Collection of Blood & Bone Marrow from Normal Volunteers & Patients for Research Purposes (No Funding) Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster  Bone Marrow Failure
7538  Collection of Blood and Bone Marrow Samples of Hematologic Diseases for Research Purposes Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster  Multiple Myeloma
A071102 16-248 A Phase II/III randomized trial of Veliparib or placebo in combination with adjuvant Temozolomide in newly diagnosed Glioblastoma with MGMT promoter Hypermethylation Main Campus Phase 2, Phase 3Glioblastoma
A08110514-1418 Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster  NSCLC (Non-small cell lung cancer)
A15121614-1419 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster  Lung
ABTC 1402 15-1529 Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma Main CampusRecurrentPhase 2Brain, Glioblastoma
AGSP 1Z15 15-519 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation Main Campus Phase 1Leukemia, Acute Myeloid (AML)
ALEX 1Z1111-245 Paroxysmal Hemoglobinuria Registry Main Campus  PNH
ALTR 1614 15-164 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer Main Campus Phase 1Head & Neck, Melanoma, NSCLC (Non-small cell lung cancer), Renal, Solid Tumors
APGD 1Y15 15-1307 A Phase 1 Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ASP2215 in Patients with Advanced Solid Tumors Main Campus Phase 1Solid Tumors
APGD 2Y15 15-1540 A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial Main Campus Phase 1, Phase 2Solid Tumors
API 1Y15 041535C An Open-label Phase 1 Study of Oral ASP5878 at Single and Multiple Doses in Patients with Solid Tumors Main Campus Phase 1Solid Tumors
APLS 1Z14 14-1275 An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH). Main Campus  Paroxysmal Nocturnal Hemoglobinuria (PNH)

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.